A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension

ovartis Pharma K.K.0 个研究点目标入组 432 人开始时间: 2013年3月18日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Patients with essential hypertension, untreated or currently taking antihypertensive therapy.
•2.Untreated patients must have an office msSBP >=150 mmHg and <180 mmHg at Visit 101 and Visit 201 if they are newly diagnosed or have not been treated with antihypertensive drugs for the 4 weeks prior to Visit 1.
•3.Treated patients must have an office msSBP >=140 mmHg and <180 mmHg at Visit 102 (or Visit 103) and msSBP >=150 mmHg and <180 mmHg at Visit 201 if they have been treated with antihypertensive drugs for the 4 weeks prior to Visit 1.
•4.All patients must have pulse pressure >60 mmHg at Visit 201. Pulse pressure is defined as msSBP- msDBP.
•5.Patients must have a difference in msSBP within +/-15 mmHg between Visit 201 (randomization) and the visit immediately prior to Visit 201.

•1.Malignant or severe hypertension (grade 3 of WHO classification; msDBP >=110 mmHg and/or msSBP >=180 mmHg)
•2.History of angioedema, drug-related or otherwise.
•3.History or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension. 4.Transient ischemic cerebral attack (TIA) during the 12 months prior to Visit 1 or any history of stroke.
•5.History of myocardial infarction, coronary bypass surgery or any percutaneous coronary intervention (PCI) during the 12 months prior to Visit 1.
•6.History of atrial fibrillation or atrial flutter during the 3 months prior to Visit 1, or active atrial fibrillation or atrial flutter on the ECG at screening.
•Other protocol-defined inclusion/exclusion criteria may apply

发起方

ovartis Pharma K.K.